Ofatumumab Plus Bendamustine in Frontline and Relapsed Chronic Lymphocytic Leukaemia (CLL)

Clinical trial NCT01520922 · COMPLETED

Trial details

NCT number: NCT01520922
Sponsor: Novartis Pharmaceuticals
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Chronic Lymphocytic Leukemia (CLL)Leukaemia, Lymphocytic, Chronic

Start date: 2012-03-01
Primary completion: 2013-02-01
Enrollment: 99

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.